• 1. An analysis of the WTC fires using CIB correlations and simple modeling
  JGQuintiere
• 2. An integrated process of CO2 capture and in situ hydrogenation to formate using a tunable ethoxyl-functionalized amidine and Rh/bisphosphine system?
  Yu-Nong Li,Liang-Nian He,Xian-Dong Lang,Xiao-Fang Liu,Shuai Zhang RSC Adv., 2014,4, 49995-50002
• 3. An investigation of new infrared nonlinear optical material: BaCdSnSe4, and three new related centrosymmetric compounds: Ba2SnSe4, Mg2GeSe4, and Ba2Ge2S6?
  Kui Wu,Zhihua Yang,Shilie Pan Dalton Trans., 2015,44, 19856-19864
• 4. An integrated cathode and solid electrolyte via in situ polymerization with significantly reduced interface resistance?
  Jialiang Yuan,Ran Dong,Yuan Li,Yang Liu,Zhuo Zheng,Yuxia Liu,Yan Sun,Benhe Zhong,Zhenguo Wu,Xiaodong Guo Chem. Commun., 2021,57, 13004-13007
• 5. Alumina grafted SBA-15 sustainable bifunctional catalysts for direct cross-coupling of benzylic alcohols to diarylmethanes?
  Chandran Rajendran,Govindaswamy Satishkumar,Charlotte Lang,Eric M. Gaigneaux Catal. Sci. Technol., 2020,10, 2583-2592

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazanaphthalenes Quinazolines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazanaphthalenes Benzodiazines Quinazolines

Professional Introduction to 2-Quinazolinepropanoic acid, 3,4-dihydro-3-(4-methylphenyl)-4-oxo (CAS No. 84312-87-8)

The compound 2-Quinazolinepropanoic acid, 3,4-dihydro-3-(4-methylphenyl)-4-oxo (CAS No. 84312-87-8) is a structurally intriguing molecule that has garnered significant attention in the field of pharmaceutical chemistry and medicinal biology. Its unique quinazoline scaffold, combined with a propanoic acid side chain and a 4-methylphenyl group, positions it as a promising candidate for further exploration in drug discovery and therapeutic applications.

The quinazoline core is a well-documented heterocyclic system known for its broad spectrum of biological activities. Quinazoline derivatives have been extensively studied for their potential in treating various diseases, including cancer, inflammation, and infectious disorders. The presence of an oxo group at the 4-position of the quinazoline ring enhances the electrophilicity of the system, making it more susceptible to nucleophilic attacks and functionalization. This feature is particularly valuable in designing molecules that can interact with biological targets through covalent bonding or non-covalent interactions.

The 3,4-dihydro moiety in the molecule suggests a more rigid structure compared to fully aromatic quinazolines. This conformational rigidity can be advantageous in optimizing binding affinity to biological targets such as enzymes and receptors. Additionally, the 3-(4-methylphenyl) substituent introduces a hydrophobic pocket that can be exploited to improve membrane permeability and oral bioavailability, which are critical factors for drug development.

In recent years, there has been a surge in research focused on quinazoline derivatives due to their demonstrated efficacy in preclinical studies. Notably, several quinazoline-based compounds have entered clinical trials for the treatment of cancer and other chronic diseases. The 2-Quinazolinepropanoic acid, 3,4-dihydro-3-(4-methylphenyl)-4-oxo derivative represents an interesting extension of this chemical class, with potential applications in modulating signaling pathways involved in disease progression.

One of the most compelling aspects of this compound is its potential as an inhibitor of kinases and other enzymes implicated in cancer cell proliferation. Kinases are critical regulators of cellular processes, and their dysregulation is often associated with tumor growth and metastasis. By targeting specific kinases, quinazoline derivatives can disrupt aberrant signaling networks and induce apoptosis or cell cycle arrest in cancer cells. Preliminary studies have shown that certain quinazoline-based inhibitors exhibit high selectivity for particular kinases while minimizing off-target effects.

The propanoic acid moiety at the C3 position of the quinazoline ring may serve as a handle for further chemical modification. This functionality can be used to attach various pharmacophores or linker groups that enhance pharmacokinetic properties or improve binding interactions with biological targets. For instance, carboxylic acid derivatives are frequently employed in drug design due to their ability to form hydrogen bonds and engage in salt formation, which can enhance solubility and bioavailability.

Another area of interest is the potential application of this compound in treating inflammatory diseases. Inflammation is a hallmark of many chronic conditions, including arthritis and autoimmune disorders. Quinazoline derivatives have been shown to modulate inflammatory pathways by inhibiting key enzymes such as COX-2 and LOX. The structural features of 2-Quinazolinepropanoic acid, 3,4-dihydro-3-(4-methylphenyl)-4-oxo make it a candidate for developing novel anti-inflammatory agents with improved efficacy and reduced side effects compared to existing therapies.

The synthesis of this compound involves multi-step organic reactions that require careful optimization to ensure high yield and purity. Advanced synthetic techniques such as palladium-catalyzed cross-coupling reactions are often employed to construct the quinazoline core efficiently. The introduction of the 3-(4-methylphenyl) group typically involves Friedel-Crafts alkylation or other aromatic substitution reactions that preserve the integrity of the quinazoline scaffold.

In conclusion, 2-Quinazolinepropanoic acid, 3,4-dihydro-3-(4-methylphenyl)-4-oxo (CAS No. 84312-87-8) is a structurally versatile molecule with significant potential in pharmaceutical research. Its unique combination of functional groups makes it an attractive scaffold for developing new drugs targeting various diseases. As research continues to uncover new biological activities associated with quinazoline derivatives, compounds like this one are likely to play a crucial role in advancing therapeutic strategies for unmet medical needs.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)